Advancement of peptide vaccines for hematologic malignancies / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 1512-1517, 2011.
Artigo
em Chinês
| WPRIM
| ID: wpr-331043
ABSTRACT
Despite recent significant advances in the treatment of hematological malignancies, relapse of this disease is of great note with the existence of the minimal residual disease (MRD). Tumour peptide vaccine seems to be one of the effective immunotherapies for eliminating tumor cells of MRD. This review focuses on the late results of clinical trails of peptide vaccination protocols targeting WT1, RHAMM, BCR-ABL, PR1 in hematological malignancies and the development of specific immune responses to PRAME and Survivin peptides. An outlook to heteroclitic peptides, new adjuvants, combined peptide vaccines and Ad-tWT1 vaccine is also given to further explore the possibility to enhance the efficacy of the peptide vaccine.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Terapêutica
/
Adjuvantes Imunológicos
/
Neoplasias Hematológicas
/
Vacinas Anticâncer
/
Vacinas de Subunidades Antigênicas
/
Alergia e Imunologia
Tipo de estudo:
Guia de Prática Clínica
Limite:
Humanos
Idioma:
Chinês
Revista:
Journal of Experimental Hematology
Ano de publicação:
2011
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS